Suppr超能文献

基质金属蛋白酶、动脉粥样硬化、蛋白尿与肾脏疾病:基于连锁分析的方法

Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches.

作者信息

Dimas G, Iliadis F, Grekas D

机构信息

First Internal Medicine Propaedeutic Department, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Greece.

出版信息

Hippokratia. 2013 Oct;17(4):292-7.

Abstract

Matrix metalloproteinases (MMPs) are important enzymes of extracellular matrix (ECM) degradation for creating the cellular environments required during development and morphogenesis. MMPs, collectively called matrixins, regulate also the biological activity of non matrix substrates such as cytokines, chemokines, receptors, growth factors and cell adhesion molecules. Enzymatic activity is regulated at multiple levels. Endogenous specific inhibitors of metalloproteinases (TIMPs) participate in controlling the local activities of MMPs in tissues. The pathological effects of MMPs and TIMPs are involved in cardiovascular disease (CVD) processes, including atherosclerosis and in a number of renal pathophysiologic alterations, both acute and chronic, linking them to acute kidney injury, glomerulosclerosis and tubulointerstitial fibrosis. This review presents an overview of the place of MMPs in atherosclerosis, proteinuria and kidney disease as a subject of considerable interest, given the differentiated and ambiguous role of MMPs in the progression of these diseases.

摘要

基质金属蛋白酶(MMPs)是细胞外基质(ECM)降解的重要酶类,在发育和形态发生过程中创造所需的细胞环境。MMPs统称为基质溶解素,还调节非基质底物如细胞因子、趋化因子、受体、生长因子和细胞粘附分子的生物活性。酶活性在多个水平受到调节。金属蛋白酶的内源性特异性抑制剂(TIMPs)参与控制组织中MMPs的局部活性。MMPs和TIMPs的病理作用涉及心血管疾病(CVD)过程,包括动脉粥样硬化以及一些急慢性肾脏病理生理改变,将它们与急性肾损伤、肾小球硬化和肾小管间质纤维化联系起来。鉴于MMPs在这些疾病进展中作用的差异和模糊性,本综述概述了MMPs在动脉粥样硬化、蛋白尿和肾脏疾病中的地位,这是一个备受关注的主题。

相似文献

2
Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease.
Adv Clin Chem. 2021;105:141-212. doi: 10.1016/bs.acc.2021.02.003. Epub 2021 Mar 9.
3
Matrix Metalloproteinases in Kidney Disease: Role in Pathogenesis and Potential as a Therapeutic Target.
Prog Mol Biol Transl Sci. 2017;148:31-65. doi: 10.1016/bs.pmbts.2017.03.001. Epub 2017 May 4.
4
Role of matrix metalloproteinases in renal pathophysiologies.
Am J Physiol Renal Physiol. 2007 Mar;292(3):F905-11. doi: 10.1152/ajprenal.00421.2006. Epub 2006 Dec 26.
5
Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
Curr Med Chem. 2018;25(15):1805-1816. doi: 10.2174/0929867325666171205143441.
6
Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.
Curr Vasc Pharmacol. 2017;15(6):557-565. doi: 10.2174/1570161115666170202162345.
8
Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Clin Chem Lab Med. 2004 Feb;42(2):121-31. doi: 10.1515/CCLM.2004.024.
9
Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
Curr Top Med Chem. 2012;12(10):1132-48. doi: 10.2174/1568026611208011132.

引用本文的文献

1
Matrix Metalloproteinase-2 and CKD Progression: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Kidney Med. 2024 Jun 6;6(8):100850. doi: 10.1016/j.xkme.2024.100850. eCollection 2024 Aug.
3
Generation of Matrix Degradation Products Using an In Vitro MMP Cleavage Assay.
Int J Mol Sci. 2022 Jun 2;23(11):6245. doi: 10.3390/ijms23116245.
5
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.
Int J Mol Sci. 2020 Dec 20;21(24):9739. doi: 10.3390/ijms21249739.
6
Injection Alleviates LPS-Induced Acute Lung Injury by Adjusting the Balance of MMPs/TIMPs Ratio.
Evid Based Complement Alternat Med. 2020 Jul 20;2020:9617081. doi: 10.1155/2020/9617081. eCollection 2020.
10
Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.
JCI Insight. 2018 Mar 22;3(6):94818. doi: 10.1172/jci.insight.94818.

本文引用的文献

1
Extracellular matrix metalloproteinase inducer is expressed in the proximal tubular epithelial cells of the human kidney.
Nephrology (Carlton). 2009 Apr;14(2):171-8. doi: 10.1111/j.1440-1797.2008.01033.x.
6
Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease.
J Am Soc Nephrol. 2007 Dec;18(12):3078-88. doi: 10.1681/ASN.2006070690. Epub 2007 Nov 14.
7
TLR4 activation mediates kidney ischemia/reperfusion injury.
J Clin Invest. 2007 Oct;117(10):2847-59. doi: 10.1172/JCI31008.
8
PINCH-1 promotes tubular epithelial-to-mesenchymal transition by interacting with integrin-linked kinase.
J Am Soc Nephrol. 2007 Sep;18(9):2534-43. doi: 10.1681/ASN.2007030315. Epub 2007 Jul 26.
9
Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin.
Semin Nephrol. 2007 May;27(3):352-62. doi: 10.1016/j.semnephrol.2007.02.006.
10
Role of matrix metalloproteinases in early hypertensive vascular remodeling.
Hypertension. 2007 Jul;50(1):212-8. doi: 10.1161/HYPERTENSIONAHA.107.089631. Epub 2007 May 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验